Trulieve’s Stock Plummets 14% as DEA Judge Temporarily Halts Cannabis Rescheduling Process
Trulieve Cannabis, a leading cannabis company, saw its stock price drop by 14% after a DEA administrative law judge paused the process of rescheduling marijuana from Schedule I to Schedule III. The decision came after a recent report from the Government Accountability Office (GAO) highlighted “gaps” in the drug scheduling process.
The pause is a significant setback for Trulieve and other cannabis companies, as rescheduling to Schedule III would have ended the Section 280E tax penalty, which has been a major obstacle for the industry. This penalty forces cannabis operators to pay taxes on gross profit rather than net profit, making it difficult for them to generate earnings and cash flow.
The GAO report, released on September 23, was used by parties opposing rescheduling to request a stay in the process. The DEA now has until October 13 to decide whether to reopen the hearing record.
The impact of this pause on Trulieve’s stock price is significant, as the company’s earnings and cash flow have been heavily dependent on the potential tax relief that would come with rescheduling. The company’s stock price has been heavily influenced by the prospect of Schedule III, and the pause has caused a significant decline in its value.
The future of Trulieve’s stock price is uncertain, and the company’s valuation is now under scrutiny. The DEA’s decision on October 13 will be closely watched, and any further delays in the rescheduling process could have significant implications for the company’s financial performance.
